Reporter brief
RCT of dasatinib plus quercetin on physical function in frail people with HIV aged 50+
What happened
This Phase II randomized controlled trial tested dasatinib plus quercetin (a senolytic combination) versus placebo in 80 people with HIV aged 50 or older who were frail or prefrail and virally suppressed on antiretroviral therapy. Participants received six cycles of the drug or placebo over 12 weeks (2 days on, 12 days off pattern), then were followed for another 12 weeks. The abstract does not report the results or whether physical function improved.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
People with HIV aged 50 or older who have been living with HIV for at least 10 years, meeting criteria for frail or prefrail diagnosis, and currently on stable antiretroviral therapy with viral suppression
- Design
- Rct
- Sample
- 80
- Journal
- National Institute of Allergy and Infectious Diseases (NIAID)
- Published
- Sep 15, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.